Safe and effective treatments for everyone

Immunotherapy has revolutionized oncology and has the potential to change the way we diagnose and treat infectious and inflammatory diseases.  We are developing innovative immunotherapies that are:

SAFE

    • Oral and nasal (no needles), fully synthetic; increases safety, deployability, geographic reach, compliance

    • Designed, studied and tested for adult and pediatric use

    • Targets are found on cancers and viruses but not normal human tissue (low risk of toxicity)

    • Fully human bispecific protein-Fc fusion that targets both PS and Man9, allowing for high therapeutic index

    • Low potential for immunogenicity

EFFECTIVE

    • Strain-agnostic

    • Infectious disease indications: Pandemic and Biodefense

    • Can be stock-piled for emergency preparedness

    • Oncology indications

    • Bypasses protein target drug resistance

    • Can be used as a decoy, with a payload (cytotoxic, immune modulator), or immune cell engager

SUSTAINABLE

    • Less invasive and mutation-agnostic technologies reduce drug development, distribution, medical and social costs

    • Eliminate health disparities by prioritizing solutions for neglected diseases and pediatric use

 

Team

Sonia Sequeira, PhD
Founder and CEO

Mahiuddin Ahmed, PhD Founder and CSO

Geoffrey Starr, JD
Corporate Counsel

Jakob Poulsen, PhD
IP Counsel, Valua

Preben Rasmussen, PhD
IP Counsel, Valua

Robert Dickey IV
Director of Finance

Strategic Partners